HUTCHMED (China) Limited (HCM)
USD 11.81
(-2.72%)
USD 11.81
(-2.72%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.27 Billion USD | 24.32% |
| 2022 | 1.02 Billion USD | -25.0% |
| 2021 | 1.37 Billion USD | 89.56% |
| 2020 | 724.11 Million USD | 55.68% |
| 2019 | 465.12 Million USD | -12.59% |
| 2018 | 532.11 Million USD | -11.01% |
| 2017 | 597.93 Million USD | 74.61% |
| 2016 | 342.43 Million USD | 49.05% |
| 2015 | 229.75 Million USD | 4.94% |
| 2014 | 218.93 Million USD | 17.92% |
| 2013 | 185.66 Million USD | -11.36% |
| 2012 | 209.46 Million USD | 7.54% |
| 2011 | 194.77 Million USD | 21.79% |
| 2010 | 159.92 Million USD | 25.18% |
| 2009 | 127.75 Million USD | 8.31% |
| 2008 | 117.95 Million USD | -7.53% |
| 2007 | 127.56 Million USD | -4.12% |
| 2006 | 133.04 Million USD | 111.58% |
| 2005 | 62.88 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.26 Billion USD | -1.48% |
| 2024 Q2 | 1.26 Billion USD | 0.0% |
| 2023 Q3 | 1.27 Billion USD | -1.37% |
| 2023 FY | 1.27 Billion USD | 24.32% |
| 2023 Q1 | 1.29 Billion USD | 26.04% |
| 2023 Q2 | 1.29 Billion USD | 0.0% |
| 2023 Q4 | 1.27 Billion USD | 0.0% |
| 2022 Q3 | 1.02 Billion USD | -13.81% |
| 2022 Q1 | 1.19 Billion USD | -12.99% |
| 2022 Q4 | 1.02 Billion USD | 0.0% |
| 2022 FY | 1.02 Billion USD | -25.0% |
| 2022 Q2 | 1.19 Billion USD | 0.0% |
| 2021 Q2 | 1.27 Billion USD | 83.65% |
| 2021 FY | 1.37 Billion USD | 89.56% |
| 2021 Q1 | 693.11 Million USD | -4.28% |
| 2021 Q4 | 1.37 Billion USD | 0.0% |
| 2021 Q3 | 1.37 Billion USD | 7.84% |
| 2020 Q4 | 724.11 Million USD | 0.0% |
| 2020 Q2 | 525.56 Million USD | 0.0% |
| 2020 Q1 | - USD | -100.0% |
| 2020 FY | 724.11 Million USD | 55.68% |
| 2020 Q3 | 724.11 Million USD | 37.78% |
| 2019 Q2 | 495.21 Million USD | -8.17% |
| 2019 Q4 | 465.12 Million USD | 2.43% |
| 2019 FY | 465.12 Million USD | -12.59% |
| 2019 Q1 | 539.29 Million USD | 1.35% |
| 2019 Q3 | 454.09 Million USD | -8.3% |
| 2018 FY | 532.11 Million USD | -11.01% |
| 2018 Q1 | - USD | -100.0% |
| 2018 Q4 | 532.11 Million USD | 0.0% |
| 2018 Q2 | 577.94 Million USD | 0.0% |
| 2017 Q2 | 344.7 Million USD | 0.0% |
| 2017 Q3 | 597.93 Million USD | 73.46% |
| 2017 Q1 | 344.7 Million USD | 0.66% |
| 2017 FY | 597.93 Million USD | 74.61% |
| 2017 Q4 | 597.93 Million USD | 0.0% |
| 2016 Q4 | 342.43 Million USD | 0.0% |
| 2016 FY | 342.43 Million USD | 49.05% |
| 2016 Q3 | 342.43 Million USD | 6.07% |
| 2016 Q2 | 322.84 Million USD | 0.0% |
| 2016 Q1 | 322.84 Million USD | 40.52% |
| 2015 Q1 | 230.36 Million USD | 5.22% |
| 2015 Q3 | 220.9 Million USD | -4.11% |
| 2015 Q4 | 229.75 Million USD | 4.01% |
| 2015 FY | 229.75 Million USD | 4.94% |
| 2015 Q2 | 230.36 Million USD | 0.0% |
| 2014 Q1 | 218.02 Million USD | 17.43% |
| 2014 FY | 218.93 Million USD | 17.92% |
| 2014 Q2 | 218.02 Million USD | 0.0% |
| 2014 Q4 | 218.93 Million USD | 0.0% |
| 2013 Q1 | 178.47 Million USD | -14.8% |
| 2013 FY | 185.66 Million USD | -11.36% |
| 2013 Q3 | 185.66 Million USD | 4.03% |
| 2013 Q2 | 178.47 Million USD | 0.0% |
| 2013 Q4 | 185.66 Million USD | 0.0% |
| 2012 Q3 | 159.72 Million USD | -19.72% |
| 2012 Q2 | 198.95 Million USD | 0.0% |
| 2012 FY | 209.46 Million USD | 7.54% |
| 2012 Q4 | 209.46 Million USD | 31.14% |
| 2011 FY | 194.77 Million USD | 21.79% |
| 2011 Q4 | 194.77 Million USD | 0.0% |
| 2010 Q2 | 143.64 Million USD | 0.0% |
| 2010 Q4 | 159.92 Million USD | 0.0% |
| 2010 FY | 159.92 Million USD | 25.18% |
| 2009 FY | 127.75 Million USD | 8.31% |
| 2009 Q4 | 127.75 Million USD | 0.0% |
| 2008 FY | 117.95 Million USD | -7.53% |
| 2007 FY | 127.56 Million USD | -4.12% |
| 2006 FY | 133.04 Million USD | 111.58% |
| 2005 FY | 62.88 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Journey Medical Corporation | 76.84 Million USD | -1565.309% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | -41.502% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -2128.871% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 18.713% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -4579.763% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -4579.763% |
| SCYNEXIS, Inc. | 128.41 Million USD | -896.615% |
| Safety Shot Inc | 12.7 Million USD | -9969.674% |
| Alpha Teknova, Inc. | 128.58 Million USD | -895.258% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | -11.936% |
| Bright Green Corporation | 17.4 Million USD | -7253.729% |
| Dynavax Technologies Corporation | 997.09 Million USD | -28.35% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -521.865% |
| Cosmos Health Inc. | 66.29 Million USD | -1830.405% |
| PainReform Ltd. | 9.93 Million USD | -12787.946% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -5433.661% |
| Embecta Corp. | 1.21 Billion USD | -5.383% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | -75.722% |
| Procaps Group, S.A. | 460.18 Million USD | -178.098% |
| Theratechnologies Inc. | 77.76 Million USD | -1545.608% |
| Harrow Health, Inc. | 311.75 Million USD | -310.506% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -8493.118% |
| Biofrontera Inc. | 27.93 Million USD | -4481.745% |
| DURECT Corporation | 45.18 Million USD | -2732.045% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 9.17% |
| Cronos Group Inc. | 1.13 Billion USD | -12.83% |
| OptiNose, Inc. | 107.72 Million USD | -1087.956% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | -171.672% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -2187.392% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -5452.85% |
| Organogenesis Holdings Inc. | 460.02 Million USD | -178.196% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -10637.993% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -1464.972% |
| Radius Health, Inc. | 1.71 Billion USD | 25.419% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -2301.659% |
| ProPhase Labs, Inc. | 91.92 Million USD | -1292.162% |
| Phibro Animal Health Corporation | 982.18 Million USD | -30.299% |
| Procaps Group S.A. | 460.18 Million USD | -178.098% |
| Alvotech | 950.09 Million USD | -34.7% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -2854.982% |
| Viatris Inc. | 47.68 Billion USD | 97.316% |
| Rockwell Medical, Inc. | 52.17 Million USD | -2352.941% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -983.681% |
| SIGA Technologies, Inc. | 254.83 Million USD | -402.194% |
| Tilray Brands, Inc. | 4.33 Billion USD | 70.48% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -367.579% |
| Shineco, Inc. | 84.17 Million USD | -1420.293% |
| PetIQ, Inc. | 868.22 Million USD | -47.401% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -15066.402% |
| Incannex Healthcare Limited | 17.04 Million USD | -7407.321% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 60.639% |
| Alimera Sciences, Inc. | 153.52 Million USD | -733.598% |
| Silver Spike Investment Corp. | 88.57 Million USD | -1344.826% |
| Assertio Holdings, Inc. | 286.41 Million USD | -346.818% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -21402.516% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -3686.782% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -3996.191% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -9560.459% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -390.098% |
| Hempacco Co., Inc. | 18.04 Million USD | -6992.874% |
| Talphera, Inc. | 20.39 Million USD | -6174.935% |
| Alvotech | 950.09 Million USD | -34.7% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | -215.091% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 22.492% |
| Currenc Group, Inc. | 141.49 Million USD | -804.494% |
| Kamada Ltd. | 351.96 Million USD | -263.603% |
| Indivior PLC | 1.95 Billion USD | 34.412% |
| Evoke Pharma, Inc. | 7.06 Million USD | -18005.18% |
| Flora Growth Corp. | 23.62 Million USD | -5316.799% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -9560.459% |
| Evolus, Inc. | 188.99 Million USD | -577.136% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 15.41% |
| Akanda Corp. | 8.83 Million USD | -14377.082% |